Cardiol TherapeuticsSTU:CT9 +3.00%32 PB Ratio is 6.82 as of Jul. 06, 2026, which is 367% above its 10-year median of 1.46. GuruFocus rates STU:CT9 with a GF Score™ of 32/100. The stock has 3 warning signs investors should review. Among 921 Drug Manufacturers companies, Cardiol Therapeutics ranks worse than 89.14% on this metric.
Cardiol Therapeutics Inc stock PB Ratio (=7.08) is close to 3-year high of 7.08.
The historical rank and industry rank for Cardiol Therapeutics's PB Ratio or its related term are showing as below:
STU:CT9'
s PB Ratio Range Over the Past 10 Years
Min: 0.56 Med: 1.46 Max: 8.25
Current: 7.08
During the past 9 years, Cardiol Therapeutics's highest PB Ratio was 8.25. The lowest was 0.56. And the median was 1.46.
STU:CT9's PB Ratio is ranked worse than 89.14% of 921
companies
in the Drug Manufacturers industry
Industry Median: 1.93
vs STU:CT9: 7.08
During the past 12 months, Cardiol Therapeutics's average Book Value Per Share Growth Rate was 1.40% per year.
During the past 3 years, the average Book Value Per Share Growth Rate was -39.80% per year.
During the past 5 years, the average Book Value Per Share Growth Rate was -22.60% per year.
During the past 9 years, the highest 3-Year average Book Value Per Share Growth Rate of Cardiol Therapeutics was 47.50% per year. The lowest was -39.80% per year. And the median was 5.10% per year.
Back to Basics: PB Ratio
Cardiol Therapeutics (STU:CT9) PB Ratio Explanation
The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.
Cardiol Therapeutics PB Ratio Related Terms
Cardiol Therapeutics PB Ratio Historical Data
* Premium members only.
The historical data trend for Cardiol Therapeutics's PB Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Cardiol Therapeutics's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Cardiol Therapeutics PB Ratio vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Cardiol Therapeutics's PB Ratio distribution charts can be found below:
* The bar in red indicates where Cardiol Therapeutics's PB Ratio falls into.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.
Cardiol Therapeutics (STU:CT9) has a PB Ratio of 6.82 as of Jul. 06, 2026. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Cardiol Therapeutics and its competitors. This is 367% above median its historical median of 1.46. Over the past decade, Cardiol Therapeutics' PB Ratio has ranged from 0.56 to 8.25. According to the industry distribution chart, Cardiol Therapeutics ranks #821 out of 921 companies in the Drug Manufacturers industry, placing it in the top 89.1%.
Is Cardiol Therapeutics' PB Ratio too high?
Cardiol Therapeutics' current PB Ratio of 6.82 is 367% above median its 10-year median of 1.46. Over the past 10 years, this metric has ranged from a low of 0.56 to a high of 8.25. The Drug Manufacturers industry median PB Ratio is 1.93. Cardiol Therapeutics' value of 6.82 is 253.4% above this industry median. Based on the distribution chart, Cardiol Therapeutics ranks #821 out of 921 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Cardiol Therapeutics has a GF Score™ of 32/100, reflecting its overall financial health beyond just this single metric.
How does Cardiol Therapeutics' PB Ratio compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Cardiol Therapeutics ranks #821 out of 921 companies for PB Ratio. This places Cardiol Therapeutics in the lower half of its industry. The industry median PB Ratio is 1.93. Cardiol Therapeutics' value of 6.82 is 253.4% above this benchmark. Historically, Cardiol Therapeutics' own PB Ratio has ranged from 0.56 to 8.25 over the past decade. While the company's 10-year median is 1.46 vs. the industry median of 1.93, Cardiol Therapeutics has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PB Ratio for a Drug Manufacturers company?
The median PB Ratio among Drug Manufacturers companies is 1.93, based on 921 companies in the industry. Companies in the top quartile (top 25%) have a PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Cardiol Therapeutics's current PB Ratio of 6.82 is 253.4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PB Ratio mean?
A high PB Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Cardiol Therapeutics and its competitors. For the Drug Manufacturers industry, the median PB Ratio is 1.93 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Cardiol Therapeutics's current PB Ratio is 6.82, which is 367% above median its own 10-year median of 1.46. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cardiol Therapeutics stock overvalued right now?
Cardiol Therapeutics (STU:CT9) has a current PB Ratio of 6.82. The current PB Ratio is 6.82, which is 367% above median its 10-year median of 1.46 and 253.4% above the Drug Manufacturers industry median of 1.93. Cardiol Therapeutics' overall GF Score™ is 32/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PB Ratio calculated?
PB Ratio is calculated from a company's financial statements. For Cardiol Therapeutics (STU:CT9), the current PB Ratio is 6.82 as of Jul. 06, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Cardiol Therapeutics Inc is a late-stage life sciences company focused on advancing the development of anti-inflammatory and anti-fibrotic therapies for heart disease. Its primary small-molecule candidate, CardiolRx, targets inflammasome pathway activation, which is involved in the development of inflammation and fibrosis in conditions such as pericarditis, myocarditis, and heart failure. The CardiolRx program includes the completed Phase II MAVERIC-Pilot study and the ongoing Phase III MAVERIC trial for the treatment of pericarditis. The ARCHER program evaluated CardiolRx in acute myocarditis through a completed Phase II study. The company is also developing CRD-38, a novel subcutaneous drug formulation for treating inflammatory heart conditions, including heart failure.
32GF Score
Get the complete analysis for STU:CT9
PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STU:CT9 has been successfully added to your 
